Albany, NY -- (SBWIRE) -- 11/10/2014 -- GBI Research, the leading business intelligence provider, has released its latest research: “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market”, which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

View Full Report
http://www.marketresearchreports.biz/analysis/211679

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/211679

The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 – RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) – are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Explore All Latest Published Reports By GBI Research
http://www.marketresearchreports.biz/publisher/2

Scope:

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:

* A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns

* Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals

* A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period

* Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets

* Key drivers and restraints that have had and are expected to have a significant impact on the market

* An overview of major licensing and co-development agreements that could affect growth trends

Reasons to Buy:

* The report will enhance your decision-making capability by allowing you to:

* Align your product portfolio to markets with high growth potential

* Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth

* Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market

* Develop key strategic initiatives based on an understanding of key focus areas and leading companies

Find category wise Reports here
http://www.marketresearchreports.biz/allcategory

Related Reports

NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

View Full Report
http://www.marketresearchreports.biz/analysis/228495

This study on novel drug delivery systems (NDDS) in cancer therapy comprises study of technologies such as embolization devices, liquid embolics and nanoparticles that offer unique approaches in cancer remedy. Several embolic agents are used by interventional radiologists for the selective occlusion of arteries supplying blood to tumors. The selection of an embolic agent depends on various factors including size of the vessel to be embolized, desired clinical outcome, duration of the vessel to be occluded, and also the intrinsic properties and behavior of the embolic agent. Nanoparticles as drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. Owing to their small size, nanoparticles exhibit unique physicochemical and biological properties, and thus help in overcoming several limitations such as poor bio-distribution, non-specific drug delivery, low therapeutic indices, and lack of water solubility which are mostly associated with conventional drug delivery.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/228495

This report studies the global market for NDDS in cancer therapy encompassing three major technologies: embolization particles, liquid embolics and nanoparticles. Each of these technologies has been analyzed in detail from product analysis, market trends, recent developments, future outlook and opportunities, to the competitive landscape. The report provides market size in terms of USD million for each technology for the period 2012 to 2020, considering the macro and micro environmental factors. In addition, the compounded annual growth rate (CAGR) of the overall NDDS in cancer therapy market and the segments has also been provided in the report for the forecast period 2014 to 2020, considering 2012 and 2013 as the base years. This report includes an elaborate executive summary, which covers a market snapshot representing key findings from the study.

United States - Pain Management Therapeutics Patients & Market Analysis

View Full Report
http://www.marketresearchreports.biz/analysis/225500

Pain management is one of the fast growing medical disciplines that reduce chronic pain. Chronic pain afflicts a large population in the United States. The United States pain management therapeutics market has huge potential for growth due to the large population that is affected by medically significant pain. The pain management market is fuelled by the segments like arthritis pain, cancer pain, back pain, fibromyalgia, migraine pain, neuropathic pain and post–operative pain relief markets. The largest segment of the United States pain management market is the arthritis while cancer is the most rapidly growing segment. The pediatric pain management market is the smallest segment for the pain management.

Download Detail Report With Complete TOC
http://www.marketresearchreports.biz/sample/sample/225500

Renub Research study titled “United States – Pain Management Therapeutics Patients & Market Analysis” provides a comprehensive assessment of the fast–evolving, high–growth of United States Pain Management Therapeutics Sector. This 73 page report with 46 Figures and 1 Table studies: 10 Pain Management Segment – Market and Patients Population.

About Marketresearchreports.biz
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Blog
http://ictmarketresearch.blogspot.com/